Pictet Asset Management Holding SA Has $127.19 Million Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Pictet Asset Management Holding SA trimmed its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 0.5% during the fourth quarter, HoldingsChannel reports. The firm owned 1,046,025 shares of the biotechnology company’s stock after selling 4,986 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Sarepta Therapeutics were worth $127,186,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in SRPT. New Age Alpha Advisors LLC acquired a new position in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $8,553,000. Norges Bank bought a new stake in Sarepta Therapeutics during the fourth quarter worth about $126,315,000. NEOS Investment Management LLC raised its stake in shares of Sarepta Therapeutics by 13.9% during the 4th quarter. NEOS Investment Management LLC now owns 1,943 shares of the biotechnology company’s stock worth $236,000 after purchasing an additional 237 shares in the last quarter. Sava Infond d.o.o. acquired a new stake in Sarepta Therapeutics in the fourth quarter valued at $365,000. Finally, WINTON GROUP Ltd acquired a new stake in Sarepta Therapeutics in the 4th quarter valued at about $678,000. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Stock Down 1.9 %

Shares of NASDAQ SRPT opened at $70.41 on Friday. The firm has a market cap of $6.83 billion, a PE ratio of 56.33 and a beta of 0.79. The company’s fifty day simple moving average is $102.66 and its 200 day simple moving average is $116.06. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 12-month low of $69.81 and a 12-month high of $173.25.

Insider Activity at Sarepta Therapeutics

In related news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares of the company’s stock, valued at approximately $2,771,187.68. This trade represents a 8.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 7.70% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have commented on SRPT shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $163.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. Royal Bank of Canada reduced their price target on Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating on the stock in a research report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a report on Wednesday, March 19th. Needham & Company LLC reissued a “buy” rating and set a $202.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Finally, Scotiabank lowered their price objective on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating for the company in a research report on Thursday, March 20th. One analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $167.41.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.